8-K: Health Catalyst Reports Strong 2024 Results and Raises 2025 Adjusted EBITDA Target

Health Catalyst announces positive financial results for 2024, including revenue of $307 million and Adjusted EBITDA of $26 million, and anticipates continued growth in 2025.

Summary

• Health Catalyst reported its fourth quarter and year-end 2024 financial results.
• Total revenue for 2024 reached $307 million, with an Adjusted EBITDA of $26 million.
• The Technology segment's revenue was $195 million for the full year and $52 million for the fourth quarter, representing a 10% year-over-year growth.
• The company anticipates a reacceleration of topline growth for full year 2025, with the Tech segment growing faster than the total business.
• The target for 2025 Adjusted EBITDA has been raised by $2 million to approximately $41 million.
• For the first quarter of 2025, the company expects total revenue of approximately $79 million and Adjusted EBITDA of approximately $4 million.
• For the full year 2025, the company expects total revenue of approximately $335 million and Technology revenue of approximately $220 million.
• The company closed the acquisition of Upfront Healthcare, strengthening its patient activation offering.
• A strategic decision was made to exit the pilot Ambulatory Operations TEMS offering by mid-2025, representing approximately $9 million of annual services revenue.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong growth in Adjusted EBITDA and a raised target for 2025. While there are some negatives, such as the exit from the pilot Ambulatory Operations TEMS offering, the overall tone is optimistic.

Positives

• Strong performance in 2024 with $307 million in total revenue and $26 million in Adjusted EBITDA.
• Technology segment showing strong growth with 10% year-over-year increase in Q4 2024.
• Increased 2025 Adjusted EBITDA target by $2 million to $41 million.
• Dollar-Based Retention (Tech + TEMS) at 102% indicates strong customer loyalty and expansion.
• Acquisition of Upfront Healthcare strengthens patient activation offering.
• Net New Platform Clients increased 91%.

Negatives

• The company is exiting the pilot Ambulatory Operations TEMS offering, which represents approximately $9 million of annual services revenue.
• Net loss of $69.5M for the full year 2024.

Risks

• Changes in laws and regulations applicable to the business model.
• Changes in market or industry conditions and regulatory environment.
• Potential loss of key clients or partners.
• Macroeconomic challenges and any new public health crisis.
• Challenges in recruiting and retaining qualified team members.

Future Outlook

Health Catalyst anticipates continued reacceleration of topline growth for full year 2025, with the Tech segment growing faster than the total business. The company raised its target for 2025 Adjusted EBITDA by $2 million, to approximately $41 million. For the first quarter of 2025, the company expects total revenue of approximately $79 million and Adjusted EBITDA of approximately $4 million. For the full year 2025, the company expects total revenue of approximately $335 million and Technology revenue of approximately $220 million.

Management Comments

• I am pleased to share that we achieved strong performance across our business, including total revenue of $307 million and Adjusted EBITDA of $26 million, said Dan Burton, CEO of Health Catalyst.
• I am encouraged with our Technology segment, which had revenue of $195 million for full-year 2024 and $52 million for the fourth quarter of 2024, which represents 10% growth year-over-year.
• I am pleased with this progress and excited that we anticipate a continued reacceleration of topline growth for full year 2025, with our Tech segment growing faster than the total business.
• Likewise, I am pleased with our profitability progress and excited that we have raised our target for 2025 Adjusted EBITDA by $2 million, to approximately $41 million.

Industry Context

Health Catalyst operates in the healthcare data and analytics market, which is experiencing growth due to the increasing demand for data-driven insights to improve clinical, financial, and operational outcomes. The company's focus on providing technology and services to healthcare organizations aligns with the industry's need for solutions that can transform complex information into actionable insights.

Comparison to Industry Standards

• Comparing Health Catalyst's performance to companies like Cerner (now Oracle Health) and Allscripts, which also provide healthcare technology solutions, Health Catalyst's revenue growth of 4% in 2024 is moderate.
• However, the 137% increase in Adjusted EBITDA suggests improved operational efficiency.
• Companies like Veeva Systems, which focus on cloud-based solutions for the life sciences industry, often command higher revenue growth rates, but operate in a different segment of the healthcare market.
• Health Catalyst's dollar-based retention rate of 102% (Tech + TEMS) is a positive indicator of customer satisfaction and compares favorably to industry benchmarks, where retention rates above 100% indicate expansion within existing customer base.
• The company's strategic decision to exit the pilot Ambulatory Operations TEMS offering is similar to moves made by other healthcare IT companies to focus on core competencies and improve profitability.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance and increased Adjusted EBITDA target.
• Employees: Potential impact due to restructuring costs and workforce reductions.
• Customers: Positive impact due to strengthened patient activation offering through the acquisition of Upfront Healthcare.

Next Steps

• The company will host a conference call to review the results on February 26, 2025.
• The company expects to file its Annual Report on Form 10-K for the year ended December 31, 2024, with the SEC on or about February 26, 2025.

Key Dates